Evaluating L-Carnitine Supplementation for Preterm Babies with Respiratory Distress Syndrome in NICU

What this Trial Is About

Researchers are studying the effects of L-carnitine supplementation in preterm newborns with Respiratory Distress Syndrome RDS. The trial aims to clarify how L-carnitine influences short-term outcomes like weight gain, discharge rates, and survival, especially given conflicting data and lack of evidence among the local population. This research focuses on neonates who may be deficient in L-carnitine and seeks to address their metabolic needs. Participants are randomly assigned to one of two groups. One group receives L-carnitine at 30 mgkgday alongside a standard care regimen consisting of 100 mg phospholipids per kg of birth weight, divided into four doses. The other group receives only the standard care regimen without L-carnitine. Both treatments are given during their stay in the neonatal intensive care unit. During the study, the babies health is closely monitored, including their weight changes and survival status over 30 days. Researchers will assess how L-carnitine supplementation affects these outcomes compared to standard care alone. The study is designed to provide evidence on the safety and potential benefits of adding L-carnitine for managing preterm neonates with RDS, with participation lasting at least 30 days post-treatment.

Effect of L-Carnitine Supplementation in Preterm Neonates